Mustjoki, Satu

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Porkka, K., Koskenvesa, P., Lundán, T., Rimpiläinen, J., Mustjoki, S., Smykla, R., Wild, R., Luo, R., Arnan, M., Brethon, B., et al. (2008) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 445

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

Giustacchini, A., Thongjuea, S., Barkas, N., Woll, P. S., Povinelli, B. J., Booth, C. A. G., Sopp, P., Norfo, R., Rodriguez-Meira, A., Ashley, N., et al. (2017) · Nature Medicine

Chronic Myeloid Leukemia TreatmentsSingle-cell and spatial transcriptomics

Cited by 403

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Dufva, O., Koski, J., Maliniemi, P., Ianevski, A., Klievink, J., Leitner, J., Pölönen, P., Hohtari, H., Saeed, K., Hannunen, T., et al. (2020) · Blood

CAR-T cell therapy researchProtein Degradation and Inhibitors

Cited by 224

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

Malani, D., Kumar, A., Brück, O., Kontro, M., Yadav, B., Hellesøy, M., Kuusanmäki, H., Dufva, O., Kankainen, M., Eldfors, S., et al. (2022) · Cancer Discovery

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 193

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia

Kuusanmäki, H., Leppä, A.-M., Pölönen, P., Kontro, M., Dufva, O., Deb, D., Yadav, B., Brück, O., Kumar, A., Everaus, H., et al. (2020) · Haematologica

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 186

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Warfvinge, R., Geironson, L., Sommarin, M. N. E., Lang, S., Karlsson, C., Roschupkina, T., Stenke, L., Stentoft, J., Olsson-Strömberg, U., Hjorth-Hansen, H., et al. (2017) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 154

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

on behalf of the International CML Foundation Genomics Alliance, Branford, S., Kim, D. D. H., Apperley, J. F., Eide, C. A., Mustjoki, S., Ong, S. T., Nteliopoulos, G., Ernst, T., Chuah, C., et al. (2019) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 149

IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models

Ågerstam, H., Hansen, N., von Palffy, S., Sandén, C., Reckzeh, K., Karlsson, C., Lilljebjörn, H., Landberg, N., Askmyr, M., Högberg, C., et al. (2016) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 98

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Mahon, F.-X., Pfirrmann, M., Dulucq, S., Hochhaus, A., Panayiotidis, P., Almeida, A., Mayer, J., Hjorth-Hansen, H., Janssen, J. J. W. M., Mustjoki, S., et al. (2024) · Journal of Clinical Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 71

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

Adnan Awad, S., Kankainen, M., Ojala, T., Koskenvesa, P., Eldfors, S., Ghimire, B., Kumar, A., Kytölä, S., Kamel, M. M., Heckman, C. A., et al. (2020) · Blood Advances

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 67

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia

Toutah, K., Nawar, N., Timonen, S., Sorger, H., Raouf, Y. S., Bukhari, S., von Jan, J., Ianevski, A., Gawel, J. M., Olaoye, O. O., et al. (2021) · Journal of Medicinal Chemistry

Histone Deacetylase Inhibitors ResearchChronic Lymphocytic Leukemia Research

Cited by 51

The use of multiplex platforms for absolute and relative protein quantification of clinical material

Christiansson, L., Mustjoki, S., Simonsson, B., Olsson-Strömberg, U., Loskog, A. S. I., & Mangsbo, S. M. (2014) · EuPA Open Proteomics

Advanced Biosensing Techniques and ApplicationsAdvanced Proteomics Techniques and Applications

Cited by 34

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

Pietarinen, P. O., Pemovska, T., Kontro, M., Yadav, B., Mpindi, J. P., Andersson, E. I., Majumder, M. M., Kuusanmäki, H., Koskenvesa, P., Kallioniemi, O., et al. (2015) · Blood Cancer Journal

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 25

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial

Flygt, H., Söderlund, S., Richter, J., Saussele, S., Koskenvesa, P., Stenke, L., Mustjoki, S., Dimitrijevic, A., Stentoft, J., Majeed, W., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 18

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

Pietarinen, P. O., Eide, C. A., Ayuda-Durán, P., Potdar, S., Kuusanmäki, H., Andersson, E. I., Mpindi, J. P., Pemovska, T., Kontro, M., Heckman, C. A., et al. (2017) · Oncotarget

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 16

Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia

Adnan Awad, S., Dufva, O., Klievink, J., Karjalainen, E., Ianevski, A., Pietarinen, P., Kim, D., Potdar, S., Wolf, M., Lotfi, K., et al. (2024) · Cell Reports Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 14

Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study

Flygt, H., Söderlund, S., Stentoft, J., Richter, J., Koskenvesa, P., Mustjoki, S., Majeed, W., Lübking, A., Dreimane, A., Markevärn, B., et al. (2021) · European Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 11